Sihuan Pharmaceutical Holdings Sustainability Profile
Sihuan Pharmaceutical Holdings Group Ltd, commonly referred to as Sihuan Pharmaceutical, is a prominent player in the pharmaceutical industry, headquartered in Beijing, China. Founded in 2001, the company has established itself as a leader in the development, manufacturing, and marketing of innovative pharmaceutical products, particularly in the fields of cardiovascular and central nervous system therapies. With a strong operational presence across major regions in China, Sihuan Pharmaceutical is renowned for its unique portfolio of prescription drugs and over-the-counter products. The company has achieved significant milestones, including the successful launch of several key medications that address critical health needs. Sihuan Pharmaceutical's commitment to research and development, coupled with its strategic market positioning, has garnered recognition within the industry, solidifying its reputation as a trusted provider of high-quality healthcare solutions.
DitchCarbon Score
How does Sihuan Pharmaceutical Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sihuan Pharmaceutical Holdings's score of 19 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sihuan Pharmaceutical Holdings's reported carbon emissions
In 2022, Sihuan Pharmaceutical Holdings reported total carbon emissions of approximately 123.3 million kg CO2e, comprising about 52.2 million kg CO2e from Scope 1 and about 71.1 million kg CO2e from Scope 2 emissions. The company has not disclosed any emissions data for 2023, nor does it provide information on Scope 3 emissions. Sihuan Pharmaceutical has not set any specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company operates without cascading emissions data from a parent organisation, maintaining its own reporting standards. Overall, Sihuan Pharmaceutical Holdings is currently in a position where it has not established significant climate commitments or reduction strategies, which may be a consideration for stakeholders focused on sustainability and environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | 55,110,190 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 36,269,070 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
How Carbon Intensive is Sihuan Pharmaceutical Holdings's Industry?
How Carbon Intensive is Sihuan Pharmaceutical Holdings's Location?
Sihuan Pharmaceutical Holdings's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sihuan Pharmaceutical Holdings has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
